EC Action Network

Great to spend time at #DDW2026 with organizations working to advance early detection in esophageal cancer. Appreciate the shared commitment to prevention and better patient outcomes. @CastleBio @TissueCypher

Don’t miss Michael Smith, MD, and Shaun O'Neil at the Foregut Foundation Course today as they highlight real-world early detection in action with the EsoGuard test. #EarlyDetectionSavesLives

Holy smokes, MATTERHORN hits OS! 🏔️🔥 We’ve been waiting for this one. After FLOT became standard for resectable gastric and GEJ adenocarcinoma, everyone wondered if adding immunotherapy could move the bar. Earlier this year, MATTERHORN showed a big EFS win for DFLOT, along with higher pCR and MPR rates, but the question was, would OS follow (and yes, maybe I was doubting this)? Now we have the answer: 🧬 OS HR 0.78 (95% CI 0.63–0.96, p=0.021) A clean, statistically significant win. 💪 Benefit seen across PD-L1 subgroups (TAP <1% HR 0.79; TAP ≥1% HR 0.79). 🧫 More nodal downstaging: ypN– 58% vs 45%, OR 1.72 (1.30–2.27). ⏱️ EFS improved in those with pCR (HR 0.29) and MPR (HR 0.32). Takeaway: Perioperative chemoimmunotherapy is here for gastric and GEJ adenocarcinoma. MATTERHORN delivers the OS confirmation we needed and cements DFLOT as standard of care (we can argue about PD1 +/- later). @OncoAlert @GutOncLab #ESMO25 🧬💥

👉🏼 Register now for our webinar on Friday, 10/10 at 3 pm Eastern us02web.zoom.us/webinar/regist… All registrants will get recording. Research now supports immunotherapy for Esophageal & GE Junction Adenocarcinoma BEFORE surgery for patients who are eligible for esophagectomy.

👉🏼 Register now for our webinar on Friday, 10/10 at 3 pm Eastern us02web.zoom.us/webinar/regist… Research now supports immunotherapy for Esophageal & GE Junction Adenocarcinoma BEFORE surgery for patients who are eligible for esophagectomy. Learn what it means for patients.

👉🏼 Today! 👈🏼 Research shows that about 25% of patients newly diagnosed with Esophageal Adenocarcinoma were told that the results of the endoscopy they had in the year before their diagnosis were of no concern. Register for our free webinar at us02web.zoom.us/webinar/regist…

👉🏼 Tomorrow 👈🏼 Research shows that about 25% of patients newly diagnosed with Esophageal Adenocarcinoma were told that the results of the endoscopy they had in the year before their diagnosis were of no concern. Register for our free webinar at us02web.zoom.us/webinar/regist…

Research shows that about 25% of patients newly diagnosed with Esophageal Adenocarcinoma were told that the results of the endoscopy they had in the year before their diagnosis were of no concern. Register for our free webinar at us02web.zoom.us/webinar/regist…

According to a study co-led by researchers at MSK and published in @NatureMedicine, a new vaccine shows encouraging early results as a potential ready-made treatment for patients with pancreatic or colorectal cancer. Unlike individualized cancer vaccines, which are tailored to each patient, ready-made vaccines can be mass-produced and stored for immediate use. The vaccine, ELI-002 2P, targets tumors with mutations (or changes) in the KRAS gene, a driving force in many cancers, and is given after surgery to prevent or delay a return of cancer. “Having this type of vaccine would make it easier, faster, and less expensive to treat a larger number of patients,” says medical oncologist and pancreatic cancer specialist @EileenMOReilly, who co-led the trial. “This gives hope for people with pancreatic and colorectal cancer who have been out of effective treatments when their disease returns.” Learn more: bit.ly/45PS4ti

A Message from ECAN's Founder & CEO ECAN has never been a job for me. It’s been my passion. Leading this movement to save lives has been one of the greatest privileges of my life. Read more at ecan.org/2025/08/12/a-m…

The Esophageal Cancer Action Network (ECAN) announced today that President and CEO, Mindy Mintz Mordecai will retire in late 2025 after nearly 17 years at ECAN. Learn more at ecan.org/2025/08/12/min…

Great to see #TissueCypher's most recent study included in the print edition of the @JCGjournal. This is the "8080" study, highlighting that #TissueCypher can identify high-risk #BarrettsEsophagus patients even in populations with low-risk clinical factors. Link below ↓↓

📢#ESMOGI2025 In Depth! Watch @YJanjigianMD & Van Cutsem discuss the MATTERHORN results. Durvalumab + FLOT in gastric/GEJ cancer: better EFS & well tolerated; even in older or PD-L1-negative patients. 👀 Watch now bit.ly/4eJaOOa #MediMix #GastricCancer #Oncology #Immunotherapy

🥊 Wear Your Support for the Fight to End Esophageal Cancer on Your Sleeve - or Visor - or Lawn Sign! 🛍️ BIG SAVINGS - at least 50% off EVERYTHING! 👉🏼 BuyPeriwinkle.org 📦 FREE SHIPPING on orders of $100 or more 🚛 We are moving: YOU GET GREAT DEALS ➡️ We get lighter boxes

🛍️ EVERYTHING in ECAN's Online Store is HALF-OFF until 7/23! ✅ Check out all the great deals at BuyPeriwinkle.org 📦 FREE SHIPPING on orders $100+ 💥 HURRY - Supplies are Limited - When they're Gone, they're Gone

“Digestive cancers, especially esophageal cancer, are among the deadliest, yet gastrointestinal esophageal reflux disease (GERD) is a common, treatable precursor,” Dr. Kenneth Chang said. “This makes esophageal cancer highly preventable. With the right strategy and implementation, we could make Orange County an esophageal cancer-free zone.” Read the @USATODAY @hoaghealth story: usatoday.com/story/sponsor-…

It’s Friday the 13th! Superstitious or not, don’t overlook persistent reflux symptoms such as: 👉Coughing 👉Sore throat 👉Hoarse voice 👉Heartburn 👉Choking while lying down 👉Erosion of tooth enamel Learn more at Get-Checked.org #HeartburnCanCauseCancer

HISTORY in the MAKING: Watch as the U.S. House of Representatives votes to pass the first bill focused on Esophageal Cancer ever introduced in Congress. Watch the proceedings and learn more at ecan.org/historic-bill-…